Home › Research › Lewy body dementia
A review of studies on vascular dementia and iron metabolism
Jing Yang, Haoran Zhao, Ying Huang. Science Progress, 2025-10-01
Topic: Risk, prevention and care in population studies
Plain-language summary
Vascular dementia (VaD) is recognized as the second most prevalent form of dementia after Alzheimer's disease, with its pathogenesis intricately associated with cerebrovascular pathologies, including chronic hypoperfusion, oxidative stress, and neuroinflammation. Recent studies have highlighted dysregulated iron metabolism as a pivotal factor in the pathogenesis of VaD; however, the precise mechanisms and therapeutic implications of this dysregulation remain insufficiently elucidated. In this article, we synthesize clinical and basic research to systematically explore the interaction between iron metabolism and VaD. Aberrant iron metabolism contributes to neuronal damage by exacerbating oxidative stress, lipid peroxidation, and ferroptosis, while cerebrovascular injuries, such as blood-brain barrier disruption and chronic inflammation, further compromise iron metabolism, thereby perpetuating a detrimental cycle. From a diagnostic standpoint, imaging modalities such as susceptibility-weighted imaging, alongside biomarkers like ferritin and soluble transferrin receptors, serve as effective instruments for detecting iron-related pathologies in VaD. At the therapeutic level, the use of chelating agents such as deferoxamine and deferiprone, in combination with antioxidants and innovative nanomaterials, has exhibited neuroprotective effects in animal models by alleviating iron-induced oxidative damage. Nevertheless, further validation is required to establish their clinical efficacy and safety. This is a narrative review. This article investigates the influence and significance of iron metabolism in the pathophysiology of VaD and explores potential therapeutic targets associated with iron metabolism, offering implications for future clinical applications.
What this study adds
Evidence grade: Low
This is a narrative review. This narrative review synthesizes research on iron metabolism in vascular dementia, noting that chelating agents such as deferoxamine and deferiprone, in combination with antioxidants and innovative nanomaterials, have exhibited neuroprotective effects in animal models. These are animal findings, so they are early and preliminary and do not yet show a treatment for people.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Yang, J., Zhao, H., & Huang, Y. (2025). A review of studies on vascular dementia and iron metabolism. Science Progress. https://doi.org/10.1177/00368504251387230
Vancouver
Yang J, Zhao H, Huang Y. A review of studies on vascular dementia and iron metabolism. Science Progress. 2025. doi:10.1177/00368504251387230. PMID: 41091821.
BibTeX
@article{yang2025-41091821,
author = {Yang, Jing and Zhao, Haoran and Huang, Ying},
title = {{A review of studies on vascular dementia and iron metabolism}},
journal = {Science Progress},
year = {2025},
doi = {10.1177/00368504251387230},
pmid = {41091821},
url = {https://doi.org/10.1177/00368504251387230}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Vascular dementia (VaD) is recognized as the second most prevalent form of dementia after Alzheimer's disease, with its pathogenesis intricately associated with cerebrovascular pathologies, including chronic hypoperfusion, oxidative stress, and neuroinflammation.
- This article investigates the influence and significance of iron metabolism in the pathophysiology of VaD and explores potential therapeutic targets associated with iron metabolism, offering implications for future clinical applications.
Why it matters
This narrative review synthesizes research on iron metabolism in vascular dementia, noting that chelating agents such as deferoxamine and deferiprone, in combination with antioxidants and innovative nanomaterials, have exhibited neuroprotective effects in animal models. These are animal findings, so they are early and preliminary and do not yet show a treatment for people.
Study details
- Study designnarrative review
- Evidence strengthLow
How this study scored 32/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Science Progress) |
| Journal's citation record | 0 / 4 | Science Progress: journal h-index 62 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | Design recorded as “narrative review”, which our rubric does not rank (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 4 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 2 / 6 | Cited 1.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 4 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Ying Huang: h-index 11 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Jinshan Hospital of Fudan University: institution h-index 119 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41091821) |
| Free to read | 2 / 2 | Free to read |
| Total | 32 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1177/00368504251387230
- PubMed: 41091821
- Original source →
- Free full text: Science Progress →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Lewy body dementia from nearby years
Also in Lewy body dementia
39 studies in the library are filed under Lewy body dementia with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Lewy body dementia hub.